
Panagiotis Panagiotidis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3403607/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. Leukemia, 2021, 35, 1745-1750.	7.2	15
2	Chronic myelogenous leukemia occurring in two brothers: The opposite sides of the same coin?. Leukemia Research Reports, 2021, 16, 100261.	0.4	1
3	A Study of Ribonucleotide Reductase mRNA Expression and Its Prognostic Role in Patients with Chronic Lymphocytic Leukemia. Blood, 2021, 138, 4678-4678.	1.4	0
4	Paternal age and specific neurological soft signs as reliable and valid neurobiological markers for the diagnosis of patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2021, , 1.	3.2	3
5	Changes in Alcohol Use Habits in the General Population, during the COVID-19 Lockdown in Greece. Alcohol and Alcoholism, 2020, 55, 702-704.	1.6	38
6	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. Haematologica, 2020, 105, 2440-2447.	3.5	31
7	A fiveâ€year followâ€up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. British Journal of Haematology, 2020, 190, 736-740.	2.5	9
8	One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study. Clinical Psychopharmacology and Neuroscience, 2020, 18, 434-444.	2.0	4
9	The effect of baseline antipsychotic status on the 12â€month outcome in initially stabilized patients with schizophrenia. Human Psychopharmacology, 2019, 34, e2712.	1.5	2
10	12-Month stability of neurological soft signs in stabilized patients with schizophrenia. Nordic Journal of Psychiatry, 2019, 73, 451-461.	1.3	5
11	A case-control study of paternal and maternal age as risk factors in mood disorders. International Journal of Psychiatry in Clinical Practice, 2019, 23, 90-98.	2.4	8
12	Neurological soft signs in familial and sporadic schizophrenia. Psychiatry Research, 2019, 272, 222-229.	3.3	8
13	Prevalence and correlates of neurological soft signs in healthy controls without family history of any mental disorder: A neurodevelopmental variation rather than a specific risk factor?. International Journal of Developmental Neuroscience, 2018, 68, 59-65.	1.6	12
14	Paternal and maternal age as risk factors for schizophrenia: a case–control study. International Journal of Psychiatry in Clinical Practice, 2018, 22, 170-176.	2.4	24
15	Neurological soft signs significantly differentiate schizophrenia patients from healthy controls. Acta Neuropsychiatrica, 2018, 30, 97-105.	2.1	17
16	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica, 2018, 103, 69-79.	3.5	35
17	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet, The, 2015, 385, 1873-1883.	13.7	296
18	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The FUTOS Registry, Blood, 2013, 122, 2735-2735	1.4	1

#	Article	IF	CITATIONS
19	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). Blood, 2013, 122, 527-527.	1.4	9
20	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood, 2013, 122, 528-528.	1.4	49
21	Advances in the treatment of geriatric depression. Aging Health, 2007, 3, 495-507.	0.3	2